Related Experiment Videos
Effective methylprednisolone dose in experimental crescentic glomerulonephritis.
1Research Institute, International Medical Center of Japan, Tokyo, Japan.
Summary
Pulse methylprednisolone (MP) therapy for crescentic glomerulonephritis shows dose-dependent benefits. While lower MP doses inhibit inflammatory gene expression, maximal therapeutic effects on reducing crescents and improving kidney function require higher doses.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Crescentic glomerulonephritis (CGN) is a severe kidney disease.
- Pulse methylprednisolone (MP) therapy is used for CGN, but optimal dosing is unclear.
- Previous studies showed MP at 30 mg/kg benefits an animal model of CGN.
Purpose of the Study:
- To determine the optimal dose of MP for treating CGN in an animal model.
- To correlate MP's therapeutic effects with its impact on chemokine gene expression.
Main Methods:
- Rats with CGN received MP (5-30 mg/kg/day) for 4 days.
- Glomerular crescents, infiltrating immune cells, and urinary protein were assessed.
- Gene expression of various chemokines was analyzed.
Main Results:
- MP significantly reduced crescents and immune cells even at 5 mg/kg.
- Maximal reduction in crescents and urinary protein occurred at 30 mg/kg MP.
- MP strongly inhibited chemokine gene expression at 5 mg/kg, but higher doses were needed for maximal clinical benefit.
Conclusions:
- MP's beneficial effects in CGN are dose-dependent.
- Maximal therapeutic efficacy of MP in this model is achieved at 30 mg/kg.
- Higher MP doses are required for optimal outcomes despite potent chemokine inhibition at lower doses.